Literature DB >> 28745972

A 20-Year Follow-up After First-Generation Autologous Chondrocyte Implantation.

Takahiro Ogura1,2, Brian A Mosier1,3, Tim Bryant1, Tom Minas1.   

Abstract

BACKGROUND: Treating articular cartilage defects is a demanding problem. Although several studies have reported durable and improved clinical outcomes after autologous chondrocyte implantation (ACI) over a long-term period, there is no report with over 20 years' follow-up.
PURPOSE: To evaluate clinical outcomes after first-generation ACI for the treatment of knees with disabling, large single and multiple cartilage defects for which patients wished to avoid prosthetic arthroplasty, with a minimum of 20 years' follow-up. STUDY
DESIGN: Case series; Level of evidence, 4.
METHODS: The authors reviewed prospectively collected data from 23 patients (24 knees; mean age, 35.4 years [range, 13-52 years]) undergoing ACI for the treatment of symptomatic, full-thickness articular cartilage lesions. A mean of 2.1 lesions per knee were treated over a mean total surface area of 11.8 cm2 (range, 2.4-30.5 cm2) per knee. Kaplan-Meier survival analysis and functional outcome scores, including the modified Cincinnati Knee Rating System, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Short Form-36 (SF-36), were used. Patients also self-reported an improvement in pain with a visual analog scale and a satisfaction survey.
RESULTS: The 20-year survival rate was 63% (95% CI, 40%-78%). The evaluation of the 15 knees with retained grafts demonstrated that all clinical scores except the WOMAC subscore for stiffness and SF-36 mental component summary score improved significantly and were sustained to 20 years postoperatively. Ninety-three percent of these patients rated knee-specific outcomes as good or excellent. The outcomes for 9 of 24 knees were considered failures, including 5 undergoing revision ACI and 4 being converted to arthroplasty at a mean of 1.7 and 5.9 years, respectively. Only 1 of 5 knees that underwent revision ACI was converted to arthroplasty at 1.9 years after the index surgery, and the other 4 patients were able to maintain their biological knee. Overall, 20 years later, 79% of patients maintained their native knee, for which they initially sought treatment, and were satisfied when evaluated.
CONCLUSION: First-generation ACI provided satisfactory survival rates and significant clinical improvements over a 20-year follow-up, which offers an important standard for comparison with newer-generation ACI technologies of the future.

Entities:  

Keywords:  articular; autologous chondrocyte implantation; cartilage; long-term follow-up; repair

Mesh:

Year:  2017        PMID: 28745972     DOI: 10.1177/0363546517716631

Source DB:  PubMed          Journal:  Am J Sports Med        ISSN: 0363-5465            Impact factor:   6.202


  31 in total

Review 1.  Surgical Management of Osteochondral Defects of the Knee: An Educational Review.

Authors:  Matthew Howell; Quintin Liao; Christopher W Gee
Journal:  Curr Rev Musculoskelet Med       Date:  2021-02-15

2.  Safety, Feasibility, and Radiographic Outcomes of the Anterior Meniscal Takedown Technique to Approach Chondral Defects on the Tibia and Posterior Femoral Condyle: A Matched Control Study.

Authors:  Gergo Merkely; Tom Minas; Takahiro Ogura; Jakob Ackermann; Alexandre Barbieri Mestriner; Andreas H Gomoll
Journal:  Cartilage       Date:  2018-10-31       Impact factor: 4.634

3.  Clinical Outcomes after Revision of Autologous Chondrocyte Implantation to Osteochondral Allograft Transplantation for Large Chondral Defects: A Comparative Matched-Group Analysis.

Authors:  Gergo Merkely; Takahiro Ogura; Jakob Ackermann; Alexandre Barbieri Mestriner; Andreas H Gomoll
Journal:  Cartilage       Date:  2019-03-22       Impact factor: 4.634

4.  Long-Term Clinical and MRI Results of Matrix-Assisted Autologous Chondrocyte Implantation for Articular Cartilage Defects of the Knee.

Authors:  Peter Cornelius Kreuz; Richard Horst Kalkreuth; Philipp Niemeyer; Markus Uhl; Christoph Erggelet
Journal:  Cartilage       Date:  2018-02-11       Impact factor: 4.634

5.  Preoperative Mental Health Has a Stronger Association with Baseline Self-Assessed Knee Scores than Defect Morphology in Patients Undergoing Cartilage Repair.

Authors:  Jakob Ackermann; Takahiro Ogura; Robert A Duerr; Alexandre Barbieri Mestriner; Andreas H Gomoll
Journal:  Cartilage       Date:  2018-07-04       Impact factor: 4.634

6.  Arthroscopic gel-type autologous chondrocyte implantation presents histologic evidence of regenerating hyaline-like cartilage in the knee with articular cartilage defect.

Authors:  Tae-Hwan Yoon; Min Jung; Chong-Hyuk Choi; Hyoung-Sik Kim; Young-Han Lee; Yun-Seok Choi; Sung-Jae Kim; Sung-Hwan Kim
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2019-06-25       Impact factor: 4.342

7.  Validation of the Oswestry Risk of Knee Arthroplasty Index (ORKA-1) for Patients Undergoing Autologous Chondrocyte Implantation.

Authors:  Jakob Ackermann; Alexandre Barbieri Mestriner; Dillon Arango; Takahiro Ogura; Andreas H Gomoll
Journal:  Cartilage       Date:  2018-08-27       Impact factor: 4.634

8.  Matrix-assisted chondrocyte transplantation with bone grafting for knee osteochondritis dissecans: stable results at 12 years.

Authors:  Luca Andriolo; Alessandro Di Martino; Sante Alessandro Altamura; Angelo Boffa; Alberto Poggi; Maurizio Busacca; Stefano Zaffagnini; Giuseppe Filardo
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2020-08-18       Impact factor: 4.342

Review 9.  Where is human-based cellular pharmaceutical R&D taking us in cartilage regeneration?

Authors:  Damla Alkaya; Cansu Gurcan; Pelin Kilic; Acelya Yilmazer; Gunhan Gurman
Journal:  3 Biotech       Date:  2020-03-06       Impact factor: 2.406

10.  Minimal Clinically Important Differences and Substantial Clinical Benefit in Patient-Reported Outcome Measures after Autologous Chondrocyte Implantation.

Authors:  Takahiro Ogura; Jakob Ackermann; Alexandre Barbieri Mestriner; Gergo Merkely; Andreas H Gomoll
Journal:  Cartilage       Date:  2018-09-15       Impact factor: 4.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.